Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC of FOLFIRINOX + sorafenib vs FOLFOX + sorafenib in advanced HCC
NCT03812783Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Nov 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan in hepatocellular carcinoma (HCC), sponsored by Sun Yat-sen University. Status: unknown.
02
Drugs
irinotecan
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03812783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812783.